Ameriprise
DNLI icon

Ameriprise’s Denali Therapeutics DNLI Stock Holding History

Ameriprise’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.72M Sell
89,534
-90,687
-50% -$1.8M ﹤0.01% 3025
2025
Q4 		$2.98M Buy
180,221
+80,660
+81% +$1.36M ﹤0.01% 2785
2025
Q3 		$1.45M Sell
99,561
-2,472
-2% -$35.5K ﹤0.01% 3177
2025
Q2 		$1.43M Buy
+102,033
New +$1.44M ﹤0.01% 3113
2025
Q1 		– Sell
-16,743
Closed -$341K – 4053
2024
Q4 		$341K Buy
16,743
+9,343
+126% +$239K ﹤0.01% 3675
2024
Q3 		$216K Buy
+7,400
New +$183K ﹤0.01% 3728

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ameriprise's DNLI Position: Q1 2026 in Review

Ameriprise reduced its Denali Therapeutics (DNLI) stake by 50% in Q1 2026, selling an estimated $1.8M and leaving 89,534 shares worth $1.72M. The position accounts for ﹤0.01% of the portfolio, ranked #3025.

Ameriprise first reported a position in DNLI in Q3 2024 and has held it in 6 quarters since. The position peaked at $2.98M in Q4 2025. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Ameriprise held 89,534 shares of Denali Therapeutics worth $1.72M as of Q1 2026.
  • Ameriprise sold 90,687 Denali Therapeutics shares in Q1 2026, an estimated $1.8M.
  • Denali Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3025 holding.
  • Ameriprise first reported a position in Denali Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Ameriprise's Denali Therapeutics position peaked at $2.98M in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.